Skip to main navigation Skip to search Skip to main content

RETRACTED: The Therapeutic Potential of Wogonin Observed in Preclinical Studies

  • Javad Sharifi-Rad
  • , Jesús Herrera-Bravo
  • , Luis A. Salazar
  • , Shabnum Shaheen
  • , Seyed Abdulmajid Ayatollahi
  • , Farzad Kobarfard
  • , Muhammad Imran
  • , Ali Imran
  • , Luísa Custódio
  • , María Dolores López
  • , Mauricio Schoebitz
  • , Miquel Martorell
  • , Manoj Kumar
  • , Hafiz Ansar Rasul Suleria
  • , William C. Cho
  • Shahid Beheshti University of Medical Sciences
  • Universidad del Azuay
  • Universidad Santo Tomás, Santiago
  • Universidad de la Frontera
  • LCWU
  • University of Karachi
  • The University of Lahore
  • Government College University
  • University of Algarve
  • Universidad de Concepción
  • ICAR - Central Institute of Research on Cotton Technology
  • University of Melbourne
  • Queen Elizabeth Hospital Hong Kong

Research output: Contribution to journalArticlepeer-review

52 Scopus citations

Abstract

Wogonin is a flavonoid found in different plants such as roots of Scutellaria baicalensis Georgi distributed mainly in Asia and Europe. Dried root extracts of S. baicalensis with high content of wogonin, popularly known as "Huang-Qin"or Chinese or baical skullcap, have been used for long time in traditional Chinese medicine. Several health benefits are attributed to wogonin and derivatives showing anti-inflammatory, antiviral, anticancer, and antioxidant effects and more recently antineurodegenerative properties. Preclinical pharmacological activities of wogonin against diverse types of cancer such as breast, colorectal, and human gastric cancer will be presented in this review. In addition, studies on oxidative stress and bioavailability of wogonin will be discussed together with antineurodegenerative potential with special focus on Alzheimer's disease. Outcomes extracted from the last preclinical studies related to therapeutic applications of wogonin will be commented and updated in this review. The scientific evidence collected in this review aims to encourage transfer of the preclinical evidence of wogonin to new clinical studies.

Original languageEnglish
Article number9935451
JournalEvidence-based Complementary and Alternative Medicine
Volume2021
DOIs
StatePublished - 2021
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'RETRACTED: The Therapeutic Potential of Wogonin Observed in Preclinical Studies'. Together they form a unique fingerprint.

Cite this